Search results
Your search for ExmaQS returned no results
Showing 1 to 15 of 24 results for exams
Showing 1 to 15 of 24 results for exams
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.
This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM13
We offer a dedicated training opportunity to achieve competency in curriculum outcome KA7.5.
We offer a dedicated training opportunity to achieve competency in curriculum outcome KA7.5.
NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .
Biographies and registered interests for members of the Technology Appraisal Committee C
NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)
Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.